<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103476</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG058691</org_study_id>
    <secondary_id>R01AG058691</secondary_id>
    <nct_id>NCT04103476</nct_id>
  </id_info>
  <brief_title>Advancing Postmenopausal Preventive Therapy</brief_title>
  <acronym>APPT</acronym>
  <official_title>Atherosclerosis Intervention With Novel Tissue Selective Estrogen Complex Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advancing Postmenopausal Preventive Therapy (APPT) is a randomized, double-blinded,
      placebo-controlled trial designed to determine the effects of tissue selective estrogen
      complex (TSEC) therapy on the progression of subclinical atherosclerosis and cognitive
      decline in 360 healthy postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To conduct a double-blinded, placebo-controlled trial to determine the effects of TSEC
      therapy on the progression of subclinical atherosclerosis in healthy postmenopausal women. A
      total of 360 postmenopausal women with a uterus who are within 6 years of menopause and 45-59
      years of age and without clinical cardiovascular disease and diabetes mellitus will be
      randomized to Bazedoxifene/Conjugated Equine Estrogen (BZA 20 mg/CE 0.45 mg) or placebo.
      Recruitment will occur over 3 years and the treatment period will be up to 3 years depending
      on when an individual is randomized. Rate of change in carotid artery intima-media thickness
      (CIMT) determined from the distal common carotid artery (CCA) far wall intima-media thickness
      (IMT) in computer image processed B mode ultrasonograms will be the primary trial endpoint.
      Arterial stiffness measured from the CCA (same location as CIMT) in computer image processed
      B mode ultrasonograms will be the secondary trial endpoint. Three composite cognitive
      measures will be used to test for randomized treatment group differences in cognition; each
      composite will be considered as co-endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized (1:1), double-blinded, placebo-controlled trial of BZA/CE versus placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization randomly determined with key to treatment groups maintained by a single individual in the data coordinating center (DCC); study product masked with matching placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid artery intima-media thickness</measure>
    <time_frame>At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization</time_frame>
    <description>Rate of change in carotid artery intima-media thickness (CIMT) determined from the distal common carotid artery (CCA) far wall intima-media thickness (IMT) in computer image processed B mode ultrasonograms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CCA stiffness</measure>
    <time_frame>At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization</time_frame>
    <description>Arterial stiffness measured from the CCA (same location as CIMT) in computer image processed B mode ultrasonograms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cognitive decline</measure>
    <time_frame>At baseline and 6 months, 1 year, 1.5 years, 2 years, 2.5 years and 3 years after randomization</time_frame>
    <description>Three composite cognitive measures will be used to test for randomized treatment group differences in cognition; each composite will be considered as co-endpoints.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>BZA/CE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg</intervention_name>
    <description>Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg</description>
    <arm_group_label>BZA/CE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a serum estradiol level &lt;30 pg/ml and cessation of regular menses &gt;6 months
             who are &lt;6 years postmenopausal and 45-59 years old.

        Exclusion Criteria:

          -  Women with a hysterectomy

          -  Clinical signs, symptoms or personal history of cardiovascular disease

          -  Diabetes mellitus or fasting serum glucose &gt;126 mg/dL

          -  Life threatening illness with prognosis &lt;5 years

          -  Cirrhosis or liver disease

          -  History of deep vein thrombosis or pulmonary embolism

          -  History of breast cancer

          -  Current use of postmenopausal hormone replacement therapy (HRT) within 1 month of
             randomization

          -  Uncontrolled hypertension (&gt;180/&gt;110 mmHg)*

          -  Plasma triglyceride levels &gt;500 mg/dL

          -  Serum creatinine &gt;2.0 mg/dL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard N. Hodis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California Atherosclerosis Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lora Maxwell, RN</last_name>
    <phone>(323) 442-2257</phone>
    <email>APPT@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janie Teran</last_name>
    <phone>(323) 442-1478</phone>
    <email>athero@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California Atherosclerosis Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Maxwell, RN</last_name>
      <phone>323-442-2257</phone>
      <email>APPT@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janie Teran</last_name>
      <phone>323-442-1478</phone>
      <email>athero@usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Howard N. Hodis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Howard N. Hodis, MD</investigator_full_name>
    <investigator_title>Professor of Medicine and Preventive Medicine, Director Atherosclerosis Research Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bazedoxifene</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

